FDAsafety guidance66% confidence
About HIV and the Center for Drug Evaluation and Research's role
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Clonazepam; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Neurology · Anticonvulsant
- Sub-indication
- General
Related signal: FDA Accepts Supplement for Clonazepam by Rubicon Research